Marketing
-
CMS unveils CAR-T proposal, with emphasis on patient outcomes
High price tags and a potential one-time administration have challenged CMS to figure out reimbursement for CAR-T cell therapies.
By Jacob Bell • Feb. 15, 2019
-
Mylan launches Advair generic at 70% discount
While a long time coming, Mylan's copycat version now looks set to take a bite out of GSK's respiratory drug sales.
By Suzanne Elvidge • Feb. 13, 2019
-
Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen
The drugmakers will make Praluent available for 60% less than the cholesterol drug's original price, a decision reflective of persistent commercial hurdles.
By Ned Pagliarulo • Feb. 11, 2019
-
Eylea's PANORAMA data give fuller view of efficacy in label expansion bid
Regeneron's blockbuster eye drug benefited certain patients with severe diabetic retinopathy, a market the big biotech is eager to break into.
By Jacob Bell • Feb. 11, 2019
-
J&J to disclose list prices in TV drug ads
Beginning in March, commercials for J&J's blockbuster blood thinner Xarelto will include list prices — a step beyond PhRMA's planned approach.
By Jacob Bell • Feb. 07, 2019
-
Mylan takes step toward knocking down key patent for Biogen's top seller
An inter partes review is under way for Tecfidera, though analysts predicted big hurdles remain to a generic of the multiple sclerosis drug.
By Jacob Bell • Feb. 07, 2019
-
Vertex fears its triplet will also face UK reimbursement battle
U.K. regulators have already been in contentious battles with the biotech over its two-drug regimens for cystic fibrosis.
By Jacob Bell • Feb. 06, 2019
-
Successful launch bolsters Libtayo's place as cornerstone therapy for Regeneron
The immunotherapy earned $15 million during its first quarter on the market, securing broad access across commercial and government insurance plans.
By Jacob Bell • Feb. 06, 2019
-
FDA draft lays out submission paths for combo products
Commissioner Scott Gottlieb said the agency will develop additional guidances outlining specific premarket considerations for combo products.
By David Lim • Feb. 06, 2019
-
Lilly lowers 2019 revenue hopes, citing Lartruvo failure
Lartruvo's clinical failure, pricing pressure and an $8 billion acquisition have caused Lilly to shift business expectations for 2019.
By Andrew Dunn • Feb. 06, 2019
-
Deep DivePharma is shuffling around jobs, but a skills gap threatens the process
Drugmakers have found difficulty luring employees who can work with the latest technologies away from the likes of Amazon and Google, for instance.
By Jacob Bell • Feb. 04, 2019
-
In hiking prices, drugmakers show some signs of tempering increases
Analysts at Raymond James found pharma price increases last month to be somewhat smaller than in January 2018 — evidence, perhaps, of some newfound restraint.
By Andrew Dunn • Feb. 04, 2019
-
Does Merck need more than Keytruda?
The cancer drug's meteoric rise is responsible for most of Merck's growth, but analysts aren't sure if that's such a good thing.
By Jacob Bell • Feb. 01, 2019
-
Pharma misses its prescription for growth
Sales forecasts for 2019 largely disappointed Wall Street, raising doubts about pharma's ability to sustain the metronomic revenue gains it's regularly enjoyed.
By Ned Pagliarulo • Jan. 31, 2019
-
J&J's Erleada has big shoes to fill, and a tough competitor to boot
Positive data from the TITAN trial supports a label expansion for the prostate drug, which would be helpful as it competes with Pfizer's Xtandi.
By Jacob Bell • Jan. 31, 2019
-
Novartis finds stability in Cosentyx amid company shake-ups
The drugmaker expects Cosentyx to grow further, providing a reliable boost as it deals with a large-scale restructuring and generic threats.
By Jacob Bell • Jan. 30, 2019
-
Anthem accelerates launch of PBM IngenioRx
The insurer now expects earnings to be greater than $19 per share in 2019, company executives said as they issued year-end and fourth quarter results.
By Samantha Liss • Jan. 30, 2019
-
Amgen's migraine lead faces early test in CVS decision
CVS lists migraine drugs from Teva and Eli Lilly as preferred over Amgen and Novartis' Aimovig, which currently holds an edge in the CGRP market.
By Ned Pagliarulo • UPDATED: Jan. 30, 2019 at 3:23 p.m.
-
Pfizer, Novartis, Amgen add to 2019 drug price hikes
Prices were increased on major products including Novartis' Cosentyx, Pfizer's Xeljanz and Amgen's Enbrel.
By Andrew Dunn • Jan. 25, 2019
-
Wall Street can't look past AbbVie's Humira problem
Greater-than-expected sales erosion from Humira biosimilars in Europe were a key contributor to AbbVie reporting a rare miss on fourth quarter revenue.
By Jacob Bell • Jan. 25, 2019
-
Senate Dems again targeting tax deductions for DTC drug ads
While the proposal has been put forward before, the Trump administration's plan to require drugmakers put prices in ads could give fresh momentum for such ideas.
By Jacob Bell • Jan. 23, 2019
-
Rising insulin prices drive jump in diabetes treatment costs: report
Higher insulin spending accounted for nearly half of a $6,000 jump in per-person spending for Type 1 diabetes care between 2012 and 2016.
By Les Masterson • Jan. 23, 2019
-
Walgreens pays $270M to settle Medicaid fraud allegations
For years, the U.S. government alleges, the pharmacy giant routinely submitted false data to improperly secure federal reimbursement for insulin pens not needed by patients.
By Suzanne Elvidge • Jan. 23, 2019
-
FDA approves third biosimilar of Roche's Herceptin
The go-ahead creates yet another threat to one of the Swiss pharma's top-selling franchises.
By Suzanne Elvidge • Jan. 22, 2019
-
Lilly suspends Lartruvo promotion after Phase 3 failure
A miss on overall survival in the pharma's ANNOUNCE study calls into question the cancer drug's earlier accelerated approval.
By Jacob Bell • Jan. 18, 2019